DATA GRAPHICS | Data Byte
Hengrui and Kailera’s oral obesity pill in line with competition
With 12.1% weight loss at 26 weeks, oral ribupatide will move to Phase III in China and Phase II globally
February 11, 2026 12:03 AM UTC
Top-line Phase II data from once-daily ribupatide — a dual GLP-1 and GIP receptor agonist from Hengrui and Kailera — add another competitor to the oral obesity race.
On Tuesday, Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Shanghai:600276; HKEX:1276) and partner Kailera Therapeutics Inc. announced results from Hengrui’s 166-patient study evaluating 10 mg, 25 mg and 50 mg oral, once-daily doses of ribupatide (KAI-9531, HRS9531) in adults with obesity. The 25 mg and 50 mg doses both led to weight loss of 12.1% versus 2.3% with placebo at 26 weeks...